Batalla, Ana <br/><br/>
Cardiovascular risk factors influence response to biological therapies in psoriasis.  [electronic resource] 

 -  Journal of the American Academy of Dermatology  Aug 2015 
 - 327-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Letter; Observational Study 
<br/><br/><label>ISSN: </label>1097-6787 
<br/><br/><label>Standard No.: </label>10.1016/j.jaad.2015.04.041  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Adult<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Biological Therapy--adverse effects<br/>Cardiovascular Diseases--diagnosis<br/>Comorbidity<br/>Cross-Sectional Studies<br/>Dose-Response Relationship, Drug<br/>Etanercept<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunoglobulin G--administration & dosage<br/>Infliximab<br/>Male<br/>Middle Aged<br/>Psoriasis--diagnosis<br/>Receptors, Tumor Necrosis Factor--administration & dosage<br/>Retrospective Studies<br/>Risk Factors<br/>Severity of Illness Index<br/>Spain<br/>Time Factors<br/>Treatment Outcome<br/>Ustekinumab